ARA-290 16mg
Janoshik
Batch ARA2-CA-26G-16
ARA-290 20mg
Non-Erythropoietic EPO Analogue
Also known as Cibinetide
ARA-290 (cibinetide) is a synthetic 11–amino acid peptide engineered from the structure of erythropoietin, studied in research for tissue-protective signaling without erythropoietic activity.
This product is intended strictly for laboratory research use within the United States. It is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable U.S. federal, state, and local regulations.
ARA-290 (cibinetide) is a synthetic 11–amino acid peptide engineered from the structure of erythropoietin, studied in research for tissue-protective signaling without erythropoietic activity.
Experimental models examine its interaction with the innate repair receptor in inflammatory and neuropathic-pain frameworks.
Third-party tested for purity, ID, quantity.
ARA-290 is a peptide derived from a region of erythropoietin responsible for tissue protection, designed to engage the innate repair receptor while avoiding the hematopoietic effects of EPO. Research has examined its anti-inflammatory and neuroprotective behavior.
Studies span small-fiber neuropathy, metabolic, and immune-modulation research models under structured conditions.
ARA-290 emerged from research separating erythropoietin’s tissue-protective signaling from its erythropoietic activity. The engineered peptide was characterized to retain cytoprotection without raising red-cell mass.
Subsequent clinical and preclinical work investigated neuropathic-pain and metabolic-control endpoints.
Research into ARA-290 focuses on innate-repair-receptor signaling and tissue-protective models. Frameworks evaluate anti-inflammatory activity, neuropathic-pain endpoints, and metabolic regulation under controlled clinical and preclinical conditions.
2 of the 4 areas below are addressed directly by a paper cited on this page.
Innate repair receptor signaling models
No paper cited on this page reports on innate, repair or receptor. This heading marks where ARA-290 20mg is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Anti-inflammatory and tissue-protection research
No paper cited on this page reports on anti, inflammatory or tissue. This heading marks where ARA-290 20mg is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Small-fiber neuropathy frameworks
Addressed on this page by van 2014. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- van, Velzen M. et al. (2014) — ARA 290 for treatment of small fiber neuropathy in sarcoidosis
Metabolic-control endpoint studies
Addressed on this page by Brines 2015. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Brines, M. et al. (2015) — ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes
The references section of this page cites 3 primary papers published between 2014 and 2016 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for ARA-290 20mg, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
ARA-290 20mg is commonly described online in connection with weight loss, appetite suppression and fat reduction. In the research literature the same compound is filed under innate repair receptor signaling models, anti-inflammatory and tissue-protection research and small-fiber neuropathy frameworks.
Of the 3 papers cited on this page, published between 2014 and 2016, 1 reports work in human participants — Brines 2015. Human data for a molecule is not the same as evidence for material supplied as a research compound: published trials use pharmaceutical-grade product under medical supervision at defined doses. What is established for the material sold here is its measured purity and content per lot.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for ARA-290 20mg is per lot, not per product. The current 20mg lot ARA2-CA-26G-16 returned 99.135% purity, 19.16 mg measured, 95.8% of the labelled 20 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
Purity is half the number. It states what fraction of the material in the vial is ARA-290 20mg; it says nothing about how much material is in the vial, and a short-filled vial can return a purity result that is entirely accurate. The figure that answers the second question is measured mass against expected content — for ARA-290 20mg, this lot measured 95.8% of its labelled 20 mg. Where a lot comes in under 100% that is published too: 20mg at 95.8%. A supplier who only publishes flattering numbers has not told you anything.
The lot code printed on the vial matches the code on the certificate for ARA-290 20mg. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy ARA-290 20mg in the United States through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
- Lyophilized storage
- −20 °C long-term; stable at room temperature in transit
- After reconstitution
- 2–8 °C
- Light
- Protect from UV and direct light
- Freeze-thaw
- Avoid repeated cycles
- Vehicle
- Bacteriostatic water in most published protocols
- Format
- Lyophilized powder
ARA-290 20mg is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 11 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.
Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
- 1 × sealed glass vial in the strength selected (20mg / 1 Vial, 20mg / 5-Pack, 20mg / 10-Pack available), batch-labelled
- The batch-linked Certificate of Analysis for the exact lot shipped
- Discreet outer packaging with no product names on the exterior
- FedEx, tracked, typically 1–3 business days domestically
- Bacteriostatic water or any other reconstitution vehicle
- Syringes, needles or filters
- Dosing, administration or protocol guidance of any kind
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of ara 290. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes
PubMedA Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets
PubMedRelated
You May Also Like
Next-generation GLP receptor agonist studied for metabolic signaling and nutrient partitioning pathways
From$79.99
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
From$39.99
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$59.99
Long-acting amylin analog engineered for appetite signaling, metabolic control, and energy balance research
From$99.99